SEOM clinical guideline for treatment of kidney cancer (2017)
Keywords: 
Kidney cancer
Systemic therapy
Molecular pathology
Issue Date: 
2018
Publisher: 
Springer
ISSN: 
1699-048X
Note: 
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://crea tivecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Citation: 
Gallardo, E. (Enrique); Méndez-Vidal, M.J. (M. J.); Perez-Gracia, J.L. (Jose Luis); et al. "SEOM clinical guideline for treatment of kidney cancer (2017)". Clinical and translational oncology. 20 (1), 2018, 47 - 56
Abstract
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.

Files in This Item:
Thumbnail
File
s12094-017-1765-4.pdf
Description
Size
402.2 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.